Esperion Therapeutics, Inc. (NASDAQ: ESPR) announced that it will acquire Corstasis Therapeutics, Inc., a commercial‑stage biopharmaceutical company focused on outpatient therapies for edema associated with cardiovascular, hepatic, and renal disease. The definitive agreement provides Esperion with an upfront cash payment of $75 million and the right to receive up to $180 million in milestone payments tied to regulatory and commercial achievements. The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions.
Corstasis’s flagship product, Enbumyst™ (bumetanide nasal spray), is the first and only FDA‑approved nasal spray loop diuretic for edema associated with congestive heart failure, hepatic, and renal disease. The drug received FDA approval on September 12, 2025, and is positioned to serve a $4 billion U.S. market of patients with congestive heart failure.
The acquisition expands Esperion’s reach into a sizable cardiovascular franchise and aligns with its Vision 2040 strategy to diversify beyond its core bempedoic acid platform. By adding Enbumyst to its portfolio, Esperion aims to broaden its cardiovascular franchise, leverage its established commercial infrastructure, and accelerate double‑digit revenue growth.
“This acquisition represents a compelling and strategically aligned opportunity that accelerates Esperion’s momentum and advances our long‑term Vision 2040. Enbumyst brings meaningful innovation to millions of patients who continue to struggle with the daily burden of diuretic therapy. Enbumyst’s novel intranasal delivery, established regulatory approval, and expanding clinical footprint make it a natural fit for our cardiovascular franchise,” said Sheldon Koenig, President and Chief Executive Officer of Esperion.
Esperion’s Q3 2025 earnings reported revenue of $87.31 million, surpassing estimates, but the company posted a net loss as it continues to invest in growth initiatives. The company is working toward profitability and scheduled its Q4 2025 earnings release for March 10, 2026. The Corstasis acquisition adds a new, high‑margin revenue stream that is expected to contribute to the company’s long‑term financial trajectory.
The deal also includes low double‑digit royalties on Enbumyst sales and potential follow‑on products, providing a recurring revenue source that complements the milestone payments. By entering the $4 billion U.S. market for congestive heart failure and expanding into hepatic and renal indications, Esperion strengthens its competitive moat and positions itself for sustained growth in the cardiovascular space.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.